Recently, Hangzhou Sanyan Biotechnology Co., Ltd. (hereinafter referred to as “Sanyan Biotech”) announced that it has completed its first round of financing, raising over RMB 10 million.
It is reported that the proceeds from this round will be primarily used for Sanyan Biotech’s core subsidiary, Hangzhou Sansheng Meijian Biotechnology Co., Ltd. (hereinafter referred to as “Sansheng Meijian”), to expand high-level production capacity of key functional ingredients, including recombinant humanized protein series and ultra–low molecular weight sodium hyaluronate. The funds will also support the in-depth upgrade of its AI-driven synthetic biology technology platform, as well as accelerate the R&D and regulatory registration of multiple medical aesthetics pipeline products in the extracellular matrix (ECM) field.
According to public information, Sanyan Biotech is a company driven by synthetic biology, focusing on high-end medical aesthetics ingredients and functional health ingredients. At present, its subsidiary Sansheng Meijian has achieved high-level expression and industrial application of several core functional ingredients, including recombinant human elastin, recombinant human fibronectin, recombinant human copper-zinc superoxide dismutase (Cu/Zn-SOD), and ultra–low molecular weight sodium hyaluronate.
These products reportedly maintain natural biological activity while enabling large-scale production with high purity and strong batch-to-batch consistency. They demonstrate significant advantages in anti-aging repair, tissue regeneration, deep hydration, and antioxidant applications, offering notable technological and commercial value.
Sanyan Biotech stated that this financing marks an important milestone in its development. Moving forward, the company will continue to increase investment in its AI-driven synthetic biology platform, GMP-grade ingredient production lines, and ECM-based medical aesthetics product portfolio, with the goal of enhancing both R&D capabilities and production capacity, and supporting the global expansion of domestically developed high-end medical aesthetics ingredients.
